Abstract: The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method.

Abstract: The present invention relates to a method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) comparing the measured level with a cut-off value; (c) determining therefrom whether a stroke or a TIA has occurred in the individual.

Abstract: The invention concerns the use of at least a synthetic compound comprising: a carrier molecule having at least a hydrocarbon chain comprising at least 10, advantageously at least 12, preferably at least 14 and not more than 300, advantageously not more than 100, preferably not more than 50, selected'among C, N, O, S, P and Si, and comprising at least two reactive functions, or capable of reacting, for grafting lateral arms on said chain, and at least two different epitopes carried by said lateral arms grafted on said carrier molecule, as standard or control for immunoassay of said biological molecules, in particular of polypeptides or proteins.

Abstract: The invention involves a synthetic peptide derived from HIV-1 virus gp41 having sequence where X615 is F or G, a method of preparing the synthetic peptide, a composition and a kit containing the synthetic peptide, and use of the synthetic peptide in immunoassays for the detection of infections caused by HIV-1 viruses.

Abstract: The present invention relates to a double-stranded probe intended for the fluorescent detection of at least one single-stranded or double-stranded target nucleic acid, comprising: —a first strand of formula X1-(L1)a-S1-S?1-(L?1)b-Y1 intended for the detection of a first strand of the target nucleic acid which comprises a sequence of formula T1-T1; —a second strand of formula X2-(L2)c-S2-S?2-(L?2)d-Y2 intended for the detection of a second strand of the target nucleic acid, if present, said second strand of the target nucleic acid comprising a sequence of formula T2-T2; wherein two of X-1, X2, Y1, and Y2 represent a fluorescent donor, while the two others represent a fluorescent acceptor, and X1 and Y2 can not both represent a fluorescent donor.

Abstract: In order to estimate the size of an initial population of nucleic acids in a sample of interest, in particular by PCR, the following steps are performed: a) providing a model of the effectiveness (En) of the PCR, the model comprising a constant stage (E0) followed by a non-constant stage, the stages being united by a changeover region having a changeover index (CEEP); b) using the model of effectiveness to express a relationship between the changeover index and a parameter representative of the initial population size; and c) determining the changeover index by comparison with the experimental measurements, and deducing therefrom the initial population size in the sample of interest.

Abstract: Synthetic peptides of the monomer type with 13 to 33 amino acids, in linear form or in a form cyclized by means of inter-cysteine disulphide bridges, have the general formula (I): ?-Z-TrpGlyCys-?-CysTyrThrSer-???(I) wherein ? is a biotinyl radical, a biocytinyl radical, a hydrogen atom, an acetyl (CH3CO—) radical, an aliphatic chain which may contain one or two thiol, an aldehyde functional group, or an amine functional group, Z represents peptide sequence -?1-Ser-?2-, -?1-Gln-?2-, or -?1-Asn-?2-, wherein -?1 represents a peptide sequence of 0 to 9 amino acids and -?2 represents a peptide sequence of 0 to 5 amino acids, ?is -Arg Gly Arg Leu Ile-(SEQ ID NO: 15), -Arg Gly Arg Leu Val-(SEQ ID NO: 16), -Arg Gly Lys Leu Ile-(SEQ ID NO: 17), -Arg Gly Lys Leu Val-(SEQ ID NO: 18), -Lys Gly Arg Leu Ile-(SEQ ID NO: 19), or -Lys Gly Arg Leu Val-(SEQ ID NO: 20), ?, attached to the —CO— group of serine, is a hydroxyl (—OH) radical, an amino (—NH2) radical, an alkoxy radical having 1 to 6 carbon atoms, a peptide sequence

Abstract: This reaction vessel support is of the type comprising at least one supporting plate (46, 48) designed to take one or more reaction vessels, and mounted rotatably about an axis of rotation (R). In one aspect of the invention, the support comprises at least one control member (94, 96) comprising releasable means (100) of coupling to a movable actuating element (40) of an actuator (10), in such a way as to enable the control member (94, 96) to be moved by the actuator (10), with the control member (94, 96) and the supporting plate (46, 48) being connected together in such a way that a movement of the control member (94, 96) by the actuator (10) is able to bring about a rotation of the supporting plate (46, 84) about the axis of rotation (R) in at least one direction of rotation. Of particular application to supports for microassay plates comprising wells laid out in a matrix arrangement.

Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies, said antigenic molecules carried by the erythrocytes consisting of antigenic molecules carried not only by the erythrocytes, but also by at least one other cell population, other than the blood group antigen molecules, said method comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes or erythrocyte membrane fragment.

Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies of an individual, comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes, erythrocyte membrane fragments or blood group antigens.

Abstract: The invention relates to a method for the in vitro diagnostic detection of an infection with a microorganism, comprising placing a biological sample, in a single assay receptacle, in the presence of particles, each carrying at least one specific detectable physical parameter, and belonging to at least two different groups, one of the groups carrying an anti-IgM capture antibody and the other group carrying a capture antigen derived from said microorganism.

Abstract: The invention relates a method to identify genotype at position 171 of the ovine PrP, and a method to select an ovine for reproduction. It also relates kits to implement these methods. The identification method of the invention comprises the steps of treating a sample of ovine biological fluid to be tested containing the PrP with a denaturing and reducing solution, immobilizing the denatured and reduced PrP, optionally via a ligand, on a solid phase, contacting the denatured, reduced and immobilized PrP with at least one detection antibody, and of detecting the possible presence of said at least one detection body, one of the ligand or of said at least one detection antibody specifically binding with the PrP having a particular allelic form at position 171. The invention finds particular application in the medical field, more particularly veterinary and sanitary fields.

Abstract: A module (1) for dry loading and unloading of a chromatography resin, a chromatography column (3) and a method for using such a module (1). The column (3) comprises an inlet valve (39) adapted to load dry chromatography resin particles and an outlet port (35) for pumping the air from de column (3). The outlet port (35) is located above the inlet valve (39).

Abstract: The invention relates to the detection of Salmonella by nucleic acid amplification. The invention provides primer and probe oligonucleotides that can be used in multiplex to detect Salmonella in real-time amplification. The oligonucleotides of the invention detect all group I serovars, and have an increased Salmonella detection range: they enable to cover the seven Salmonella groups. They also have an increased sensitivity, without loss in specificity.

Abstract: The invention relates to synthetic peptides having sequence (III), which are derived from HIV-1 virus gp41 and which can be used in immunoassays for the detection of infections caused by HIV-1 viruses. The invention also relates to the method of preparing said peptides, to compositions and kits containing same and to the use thereof for diagnostic purposes. The invention further relates to immunoassays which use said peptides for the detection of anti-HIV virus antibodies.

Abstract: The invention concerns nucleic sequences of plasmid origin, present in bacteria of the group enterohemorrhagic Escherichia coli (EHEC), the use of said sequences for searching for EHEC, in particular those having genes coding for enterohemolysin and intimin virulence factors, and more particularly for specific detection of the O157:H7 serotype. The invention also concerns a method using said sequences and detection kits containing them.

Abstract: The invention relates to an in vitro diagnosis of heart failure. More specifically, the invention relates to specific antibodies of a peptide domain which is situated on either side of hinge region R76S77 of proBNP(1-108). In particular, the invention relates to a method of obtaining the aforementioned antibodies and to the use thereof in detecting blood proBNP(1-108) with the exception of BNP(1-76) and BNP(77-108). The invention also relates to a method of detecting blood proBNP(1-108), reagents and a kit for same.

Abstract: The present invention relates to the detection of HIV by amplification and PCR-based methods.

Abstract: The present invention relates to the use of both RD9 and IS6110 as nucleic acid targets, for the specific and sensitive detection of a mycobacterium of the Mycobacterium tuberculosis complex (MtbC), and/or for the specific and sensitive discrimination of Mycobacterium tuberculosis and Mycobacterium canetti on one hand, from the other strains of said MtbC on the other hand. Advantageously, said MtbC detection and said species discrimination can be made in a single amplification run (multiplex PCR). The means of the invention are advantageous tools for the diagnosis of tuberculosis.

Abstract: The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method.